Home › Calculator › ABBV Dividend Calculator 2026
ABBV Dividend DRIP Calculator 2026
2.52% YieldHealthcareAbbVie Inc. · NYSE
Price: $271.36 · Annual div: $6.83/share · Frequency: quarterly · Payout ratio: 288% · Ex-div: 2026-10-15
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ABBV pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ABBV snowball 📈
$10,000 in ABBV → $20.8K in 10 years · $55.95/month
About AbbVie Inc. (ABBV) — Dividend Analysis 2026
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Compare ABBV with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ABBV DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ABBV position with:
🌍 ABBV Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ABBV.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.52% | -0.28% | $252 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.14% | -0.66% | $214 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.02% | -0.78% | $202 / yr |
| 🇬🇧 UK ISA | 0% | 2.52% | -0.28% | $252 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.30% | -0.50% | $230 / yr |
| 🇨🇦 TFSA | 0% | 2.52% | -0.28% | $252 / yr |
| 🇨🇦 CA Taxable | 25% | 1.89% | -0.91% | $189 / yr |
| 🇦🇺 Super (pension) | 15% | 2.14% | -0.66% | $214 / yr |
| 🇦🇺 AU Taxable | 30% | 1.76% | -1.04% | $176 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.86% | -0.94% | $186 / yr |
| 🇫🇷 FR Taxable | 30% | 1.76% | -1.04% | $176 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ABBV Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $6.83/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ABBV Dividend Payment Schedule
ABBV pays quarterly — 4 times per year. Ex-div: 2026-10-15.
📊 ABBV vs Healthcare Benchmarks
How ABBV compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ABBV sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ABBV Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-09-30 | 59 | $261.59 | $15.4K | ||
| A-Award | 2026-09-30 | 129 | $261.59 | $33.7K | ||
| M-Exempt | 2026-08-14 | 32,710 | $79.02 | $2.58M | ||
| Sale | 2026-08-14 | 32,710 | $250.00 | $8.18M | ||
| M-Exempt | 2026-08-14 | 32,710 | $79.02 | $2.58M | ||
| A-Award | 2026-06-30 | 134 | $251.64 | $33.7K | ||
| A-Award | 2026-06-30 | 62 | $251.64 | $15.6K | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — | ||
| A-Award | 2026-05-08 | 1,118 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare ABBV with peers: ABBV vs AMGN · ABBV vs AZN · ABBV vs GILD
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where ABBV earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ABBV dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
AbbVie Inc. (ABBV) is currently trading at $271.36, trading near its 52-week high. The current dividend yield is 2.52% based on an annual payout of $6.83 per share.
AbbVie Offers Solid Dividend Growth Backed by Healthcare Stability, Though Payout Metrics Require Caution
AI SummaryAbbVie Inc., a healthcare giant with a $483.5B market capitalization, rewards shareholders with a 2.50% dividend yield based on an annual payout of $6.83. The company boasts a respectable 5-year dividend CAGR of 7.3%, highlighting its commitment to consistent shareholder returns. However, the high price tag of $273.64 and a lofty P/E ratio of 115.5 reflect significant valuation pressures. From a sustainability perspective, AbbVie's dividend safety warrants close monitoring. The reported payout ratio stands at an unsustainable 288%, driven by recent accounting charges and earnings fluctuations rather than pure cash flow inadequacy. While the healthcare sector generally provides defensive revenue streams, investors must evaluate whether future earnings growth can bridge the wide gap between
- High payout ratio of 288% threatening near-term dividend safety
- Lofty P/E ratio of 115.5 indicating potential overvaluation
Generated by AI using live market data. For educational purposes only — not financial advice.
Latest ABBV News
LiveHow investors use the ABBV dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.